C-RZPYLento Bio
small molecules, lens repair, eye drops
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RZPY
C-RZPYC-RZPYsmall molecules, lens repair, eye drops
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Lento Bio small molecules, lens repair, eye drops
Lento Bio develops small molecule therapeutics for age-related vision loss, beginning with the lens. Its lead program LB-01 is a topical eye drop designed to reverse molecular damage that stiffens the crystalline lens. The company describes its approach as restoring natural physiology rather than masking symptoms.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Lento Bio — Far from goals · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (3 programs at undisclosed).…
Source: Deterministic